Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 16/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9930167 | 0.90 | MAOA (0.36) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL9964844 | 0.90 | WDR5 (0.38) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL9930158 | 0.88 | WDR5 (0.32) | MAOAMAOBWDR5 | |
| SCHEMBL4555097 | 0.87 | WDR5 (0.38) | MAOAMAOBWDR5 | |
| SCHEMBL14069657 | 0.86 | WDR5 (0.31) | MAOAMAOBWDR5 | |
| SCHEMBL14069648 | 0.85 | MAOA (0.36) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL4553635 | 0.83 | MAOA (0.38) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL14069388 | 0.83 | MAOA (0.38) | MAOAMAOBCYP3A4CYP2D6KCNH2 | |
| SCHEMBL9930649 | 0.83 | MAOB (0.45) | MAOAMAOBKCNH2WDR5 | |
| SCHEMBL9964842 | 0.83 | MAOA (0.38) | MAOAMAOBCYP3A4CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| WO-2008108988-A1 | ANTIMICROBIAL HETEROCYCLIC COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | MAOA 1058/4885MAOB 761/4885CYP3A4 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.